Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.36 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607850 | 0.93 | CREBBP (0.39) | CREBBPEP300MAPK10MLLT3MLLT1 | |
| SCHEMBL6164284 | 0.91 | CREBBP (0.36) | CREBBPEP300MAPK10MLLT3MLLT1 | |
| SCHEMBL6165821 | 0.86 | HSD11B1 (0.33) | CREBBPEP300MEN1KMT2A | |
| SCHEMBL6166837 | 0.81 | MLLT3 (0.42) | CREBBPEP300MAPK10MLLT3MLLT1 | |
| SCHEMBL6163707 | 0.81 | USP30 (0.36) | — | |
| SCHEMBL6164138 | 0.81 | NPC1 (0.32) | CREBBPEP300CCR2 | |
| SCHEMBL6164841 | 0.81 | EP300 (0.32) | CREBBPEP300MEN1KMT2A | |
| SCHEMBL6163574 | 0.81 | SLC16A3 (0.33) | CREBBPEP300 | |
| SCHEMBL6164700 | 0.81 | EP300 (0.32) | CREBBPEP300 | |
| SCHEMBL6165935 | 0.81 | EP300 (0.32) | CREBBPEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | CREBBP 970/4885EP300 3193/4885MAPK10 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.